What is the HLB Biostep Co., Ltd. stock price forecast?

HLB Biostep Co., Ltd. is currently trading at ₩3,435. View real-time AI analysis on Alpha Lenz.

What is HLB Biostep Co., Ltd. insider trading activity?

View the latest insider trading data for HLB Biostep Co., Ltd. on Alpha Lenz.

What is HLB Biostep Co., Ltd.'s P/E ratio?

HLB Biostep Co., Ltd.'s P/E ratio is -3.2.

HLB Biostep Co., Ltd.

KRX · 278650

₩3,435+290(+9.22%)Market closed

Ask about HLB Biostep Co., Ltd.'s future dividend policy...

Alpha Chat Insight

“HLB Biostep Co., Ltd. trades at a P/E of -3.2 (undervalued) with modest ROE of -18.2%.”

Ask for details →

Company Overview

HLB Biostep Co., Ltd. is a company specializing in the production and distribution of biotechnology products and services. Its primary function is to develop innovative solutions in the life sciences sector, with a focus on producing high-quality bioproducts that cater to a wide range of scientific and industrial applications. The company operates within various industries, including pharmaceuticals, healthcare, and agricultural biotechnology. HLB Biostep Co., Ltd. is known for its cutting-edge research and development, contributing to advancements in medical and scientific research methodologies. It plays a crucial role in the global biotechnology market by providing essential tools and services that support critical research and development activities across its target sectors. Its strategic operations and continuous innovation position HLB Biostep as a key player in advancing biotechnological solutions both locally and internationally.

CEO백성진

Websitehttps://hlbbiostep.com

SectorHealthcare

IndustryBiotechnology

Employees146

Company Statistics

FY 2025

Profile

₩59,880,280,260Market Cap

₩74,050,095,460Revenue

17.43MShares Out

146Employees

Margins

76.20%Gross

-10.13%EBITDA

-11.64%Operating

-23.67%Pre-Tax

-27.35%Net

Valuation

-3.16P/E

0.62P/B

0.81EV/Sales

-7.22EV/EBITDA

58.33P/FCF

Growth (CAGR)

-4.97%Rev 3Yr

4.82%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-12.51%ROA

-18.22%ROE

-9.56%ROIC

Financial Health

₩41,156,949,830Cash & Cash Equivalents

₩13,481,300,920Net Debt

54.13%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“HLB Biostep Co., Ltd. trades at a P/E of -3.2 (undervalued) with modest ROE of -18.2%.”

Ask for details →

Frequently Asked Questions

HLB Biostep Co., Ltd. (ticker: 278650) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 146 employees. Market cap is $59.9B.

The current price is ₩3,435 with a P/E ratio of -3.16x and P/B of 0.62x.

ROE is -18.22% and operating margin is -11.64%. Annual revenue is $74.1B.